Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (previously presented): A compound of formula **(I)**:



(I)

wherein:

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom; wherein if Ring A contains an additional nitrogen atom that nitrogen may be optionally substituted by R^7;

R^1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C_{1-6}alkyl, C_{1-6}alkoxy, C_{2-6}alkenyl or C_{2-6}alkynyl;

p is 0-4; wherein the values of R^1 may be the same or different;

R^2 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, azido, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkanoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, carbocyclyl-R^{34}-, heterocyclyl-R^{35}-, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl or *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl; wherein R^2 independently may be optionally substituted on carbon by one or more R^8; or R^2 is -NHR^9, -NR^{10}R^{11} or -O-R^{12};

q is 0-2; wherein the values of R^2 maybe the same or different;

R^3 is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-3}alkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, C_{1-3}alkoxy, C_{1-3}alkanoyl,

N-(C_{1-3}alkyl)amino, *N,N*-(C_{1-3}alkyl)$_2$amino, C_{1-3}alkanoylamino, *N*-(C_{1-3}alkyl)carbamoyl, *N,N*-(C_{1-3}alkyl)$_2$carbamoyl, C_{1-3}alkylS(O)$_a$ wherein a is 0 to 2, *N*-(C_{1-3}alkyl)sulphamoyl or *N,N*-(C_{1-3}alkyl)$_2$sulphamoyl; wherein R^3 may be independently optionally substituted on carbon by one or more R^{13};

n is 0 to 2, wherein the values of R^3 may be the same or different;

R^4 is hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, carbocyclyl or a carbon-linked heterocyclyl; wherein R^4 may be optionally substituted on carbon by one or more R^{14}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{15};

R^5 and **R^6** are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2, C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, C_{3-8}cycloalkyl or a 4-7 membered saturated heterocyclic group; wherein R^5 and R^6 independently of each other may be optionally substituted on carbon by one or more R^{16}; and wherein if a 4-7 membered saturated heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17};

R^7, **R^9**, **R^{10}**, **R^{11}** and **R^{12}** are independently selected from C_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, C_{2-6}alkenylsulphonyl, C_{2-6}alkynylsulphonyl, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)carbamoyl, carbocyclyl, heterocyclyl, carbocyclyl-R^{18}- or heterocyclyl-R^{19}-; wherein R^7, R^9, R^{10}, R^{11} and R^{12} may be independently optionally substituted on carbon by a group selected from R^{20}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R^{21};

R^{14} and **R^{20}** are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, C_{2-6}alkenyloxy, C_{2-6}alkynyloxy, C_{1-6}alkoxyC_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkoxyC_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkanoyloxy, *N*-(C_{1-6}alkyl)amino, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkanoylamino, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{1-6}alkylS(O)$_a$ wherein a is 0 to 2,

C_{1-6}alkoxycarbonyl, *N*-(C_{1-6}alkyl)sulphamoyl, *N,N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC_{1-6}alkyl-R^{22}-, heterocyclylC_{1-6}alkyl-R^{23}-, carbocyclyl-R^{24}- or heterocyclyl-R^{25}-; wherein R^{14} and R^{20} may be independently optionally substituted on carbon by one or more R^{26}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{27};

R^{18}, **R^{19}**, **R^{22}**, **R^{23}**, **R^{24}**, **R^{25}**, **R^{34}** or **R^{35}** are independently selected from -O-, -N(R^{28})-, -C(O)-, -N(R^{29})C(O)-, -C(O)N(R^{30})-, -S(O)$_s$-, -SO_2N(R^{31})- or -N(R^{32})SO_2-; wherein **R^{28}**, **R^{29}**, **R^{30}**, **R^{31}** and **R^{32}** are independently selected from hydrogen or C_{1-6}alkyl and s is 0-2;

R^{15}, **R^{17}**, **R^{21}** and **R^{27}** and are independently selected from C_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R^{15}, R^{17}, R^{21} and R^{27} independently of each other may be optionally substituted on carbon by on or more R^{33}; and

R^{8}, **R^{13}**, **R^{16}**, **R^{26}** and **R^{33}** are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;
or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein:

Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen or oxygen atom; wherein if Ring A contains an additional nitrogen atom that nitrogen may be optionally substituted by R^7; wherein

R^7 is selected from C_{1-6}alkanoyl, C_{1-6}alkylsulphonyl, C_{2-6}alkenylsulphonyl, carbocyclyl-R^{18}- or heterocyclyl-R^{19}-; wherein R^7 may be independently optionally substituted on carbon by a group selected from R^{20}; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by R^{21};

R^{18} and R^{19} are -C(O)-;

R^{20} is selected from halo, cyano, hydroxy, C_{1-6}alkoxy, C_{2-6}alkynyloxy, C_{1-6}alkanoyloxy, *N,N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkylS(O)$_a$ wherein a is 2 or heterocyclyl; wherein R^{20} may be optionally substituted on carbon by one or more R^{26};

R^{21} is C_{1-6}alkyl; and

R^{26} is hydroxy;

or a pharmaceutically acceptable salt thereof.

Claim 3 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein R^1 is halo or C_{1-6}alkyl or a pharmaceutically acceptable salt thereof.

Claim 4 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein p is 0 or 1 or a pharmaceutically acceptable salt thereof.

Claim 5 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein:

R^2 is selected from hydroxy, amino, azido, C_{1-6}alkyl, *N*-(C_{1-6}alkyl)carbamoyl, *N,N*-(C_{1-6}alkyl)$_2$carbamoyl, carbocyclyl-R^{34}-, -NHR^9 or -O-R^{12};

R^9 and R^{12} are independently selected from C_{1-6}alkanoyl or C_{1-6}alkylsulphonyl; wherein R^9 and R^{12} may be independently optionally substituted on carbon by a group selected from R^{20};

R^{20} is hydroxy; and

R^{34} is -N(R^{29})C(O)-; wherein R^{29} is hydrogen;

or a pharmaceutically acceptable salt thereof.

Claim 6 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein R^3 is halo or a pharmaceutically acceptable salt thereof.

Claim 7 (previously presented): A compound of formula **(I)** as claimed in claim 1wherein n is 0 or 1 or a pharmaceutically acceptable salt thereof.

Claim 8 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein:

R^4 is C_{1-6}alkyl or carbocyclyl; wherein R^4 may be optionally substituted on carbon by one or more R^{14}; wherein

R^{14} is carbocyclyl;

or a pharmaceutically acceptable salt thereof.

Claim 9 (previously presented): A compound of formula **(I)** as claimed in claim 1 wherein:

R^5 and R^6 are independently selected from hydrogen or C_{1-6}alkyl; wherein R^5 and R^6 independently of each other may be optionally substituted on carbon by one or more R^{16}; wherein

R^{16} is selected from methoxy;

or a pharmaceutically acceptable salt thereof.

Claim 10 (previously presented): A compound of formula **(I)**, as claimed in claim 1, wherein:

Ring A, R^2 and q together form piperazin-1-yl, morpholino, 4-mesylpiperazin-1-yl, 4-acetylpiperazin-1-yl, 4-(2-acetoxyacetyl)piperazin-1-yl, 4-(2-hydroxyacetyl)piperazin-1-yl, 4-(2-chloroacetyl)piperazin-1-yl, 4-(2-methoxyacetyl)piperazin-1-yl, (3-methoxypropanoyl)piperazin-1-yl, (3-hydroxy-3-methylbutanoyl)piperazin-1-yl, (3-hydroxy-2,2-dimethylpropanoyl)piperazin-1-yl, ((R)-3-methyl-2-hydroxybutanoyl)piperazin-1-yl, ((S)-3-methyl-2-hydroxybutanoyl)piperazin-1-yl, 4-(2-dimethylaminoacetyl)piperazin-1-yl, 4-[2-(dimethylamino)ethylsulphonyl]piperazin-1-yl, 4-[2-(methoxy)ethylsulphonyl]piperazin-1-yl, 4-[2-(hydroxy)ethylsulphonyl]piperazin-1-yl,

4-(cyclopropylcarbonyl)piperazin-1-yl, 4-(1-hydroxycyclopropylcarbonyl)piperazin-1-yl,
4-(1-cyanocyclopropylcarbonyl)piperazin-1-yl, 4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl,
4-((R)-2-hydroxypropanoyl)piperazin-1-yl, 4-((S)-2-hydroxypropanoyl)piperazin-1-yl,
4-((R)-2-methoxypropanoyl)piperazin-1-yl, 4-((S)-2-methoxypropanoyl)piperazin-1-yl,
4-((R)-tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl,
4-((S)-tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl, 4-(isobutyryl)piperazin-1-yl,
4-((R)-2-hydroxybutanoyl)piperazin-1-yl, 4-((S)-2- hydroxybutanoyl)piperazin-1-yl,
(R)-3-acetylaminopyrrolidin-1-yl, (S)-3-acetylaminopyrrolidin-1-yl,
(R)-2-(cyclopropylaminocarbonyl)pyrrolidin-1-yl, (R)-2-(*N*-methylcarbamoyl)pyrrolidin-1-yl,
(S)-2-(*N,N*-dimethylcarbamoyl)pyrrolidin-1-yl, 4-(ethenylsulphonyl)piperazin-1-yl,
4-[2-(2-propyn-1-yloxy)acetyl]piperazin-1-yl, 4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl,
4-(3-dimethylaminopropanoyl)piperazin-1-yl,
4-[2-(*N*-methyl-*N*-hydroxymethylamino)acetyl]piperazin-1-yl,
4-[3-hydroxy-2-(hydroxymethyl)propanoyl]piperazin-1-yl,
4-[2-(1,2,3,4-tetrazol-1-yl)acetyl]piperazin-1-yl, 4-[2-(1,2,3,4-tetrazol-5-yl)acetyl]piperazin-1-yl,
4-(1-methyl-L-prolyl)piperazin-1-yl, 4-[2-(mesyl)acetyl]piperazin-1-yl,
4-(2,2-difluoroacetyl)piperazin-1-yl, 4-[2-(pyrrolidin-1-yl)acetyl]piperazin-1-yl,
4-[2-(morpholino)acetyl]piperazin-1-yl, 4-[2-(diethylamino)acetyl]piperazin-1-yl,
4-(propionyl)piperazin-1-yl, 4-(3-hydroxypropionyl)piperazin-1-yl,
4-[2-(azetidin-1-yl)acetyl]piperazin-1-yl, (R)-3-aminopyrrolidin-1-yl,
(S)-3-aminopyrrolidin-1-yl, (3*R*,5*S*)-4-acetyl-3,5-dimethylpiperazin-1-yl,
(2*S*,5*R*)-4-acetyl-2,5-dimethylpiperazin-1-yl, (2*RS*,6*SR*)-2,6-dimethylmorpholin-4-yl]phenyl,
3-hydroxyazetidin-1-yl, 3-acetylaminoazetidin-1-yl, 3-(2-hydroxyacetylamino)azetidin-1-yl,
3-mesylaminoazetidin-1-yl, 3-mesyloxyazetidin-1-yl, 3-azidoazetidin-1-yl, 3-aminoazetidin-1-yl,
(3*R*)-3-{[(2*S*)-2-hydroxypropanoyl]amino}pyrrolidin-1-yl,
(3*S*)-3-{[(2*S*)-2-hydroxypropanoyl]amino}pyrrolidin-1-yl,
(3*S*)-3-(glycoloylamino)pyrrolidin-1-yl and (3*R*)-3-(glycoloylamino)pyrrolidin-1-yl;

R^1 is fluoro, chloro or methyl;

p is 0 or 1;

R^2 is selected from hydroxy, amino, azido, methyl, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, acetamido, {[(2*S*)-2-hydroxypropanoyl]amino}, glycoloylamino, mesylamino, 2-hydroxyacetamido, mesyloxy or *N*-cyclopropylcarbamoyl.

q is 0-2; wherein the values of R^2 maybe the same or different;

R^3 is 5-fluoro or 5-chloro;

n is 0 or 1;

R^4 is ethyl, isopropyl, isobutyl, cyclobutyl or cyclopropylmethyl; and

R^5 and R^6 are independently selected from hydrogen, methyl, ethyl, methoxymethyl, propyl;

or a pharmaceutically acceptable salt thereof.

Claim 11 (previously presented): A compound of formula **(I)**, as claimed in claim 1, selected from:

2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine hydrochloride;

2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidine;

(2*S*)-1-[4-(4-{[5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]-1-oxopropan-2-ol;

2-[4-(morpholino)anilino]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine;

2-{4-[4-(acetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-5-fluoropyrimidine;

2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidine;

5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)-*N*-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}pyrimidin-2-amine;

N-[4-(4-acetylpiperazin-1-yl)-3-fluorophenyl]-5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine;

N-[4-(4-acetylpiperazin-1-yl)-3-fluorophenyl]-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-amine; and

(2*R*)-1-[4-(4-{[5-fluoro-4-(1-isopropyl-2-methyl-1*H*-imidazol-5-yl)pyrimidin-2-yl]amino}phenyl)piperazin-1-yl]-1-oxopropan-2-ol;
or a pharmaceutically acceptable salt thereof.

Claim 12 (currently amended): A process for preparing a compound of formula **(I)**, as claimed in claim 1, or a pharmaceutically acceptable salt thereof, which process~~, wherein variable groups are, unless otherwise specified, as defined claim 1,~~ comprises ~~of~~:
Process a) ~~reaction of~~ reacting a pyrimidine of formula **(II)**:



(II)

wherein L is a displaceable group; with an aniline of formula **(III)**:



(III)

or

Process b) reacting a compound of formula **(IV)**:



(IV)

with a compound of formula **(V)**:



(V)

wherein T is O or S; R^x may be the same or different and is selected from C_{1-6}alkyl; or

Process c) reacting a pyrimidine of formula **(VI)**:



(VI)

wherein X is a displaceable group; with a heterocyclyl of formula **(VII)**:



(VII)

or

Process d) for compounds of formula **(I)**; reacting a pyrimidine of formula **(VIII)**



(VIII)

with a compound of formula **(IX)**:



(IX)

where Y is a displaceable group;

and thereafter optionally:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups; and/or

iii) forming a pharmaceutically acceptable salt .

Claim 13 (previously presented): A pharmaceutical composition which comprises a compound of formula **(I)** or a pharmaceutically acceptable salt thereof, as claimed in claim 1, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 14-21 (canceled)

Claim 22 (currently amended): A method of treating ~~cancers, solid tumours and leukaemias, fibroproliferative and differentiative disorders, psoriasis,~~ rheumatoid arthritis, ~~Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis,~~

~~arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation~~, in a warm-blooded animal, ~~such as man,~~ in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

Claim 23 (currently amended): A method of treating ~~cancer~~ rheumatoid arthritis in a warm-blooded animal, ~~such as man,~~ in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein the animal is man.

Claims 24-30 (canceled)